MOUNT LAUREL, N.J., Nov. 29 /PRNewswire/ -- ImpactRx, Inc., the pioneering force in measuring the impact of pharmaceutical promotion on the behavior of the nation’s highest prescribing physicians, today announced that its Board of Directors has named Richard C. Altus as President and Chief Executive Officer. Mr. Altus was installed as ImpactRx’s President and acting CEO in May of this year. This decision by the Board eliminates the acting qualification from Mr. Altus’ title.
Source: ImpactRx, Inc.
· Richard C. Altus, president and CEO of ImpactRx. · Click Here to Download Image
Per Lofberg, Chairman of ImpactRx’s Board of Directors and President of Merck Capital Ventures, an investor in ImpactRx, praised Mr. Altus’ performance to date. “During his first six months on the job, Rich has proven to be an effective leader and has continued to build on the company’s successes. He has established a clear strategic direction for the company and has made real progress in ensuring that the organization executes its business objectives.” Lofberg also stated, “This action by the Board to fully endorse him as President and CEO is confirmation of our confidence in Rich’s ability to lead ImpactRx into the future.”
Altus, who joined ImpactRx in 2002, has more than twenty-five years of financial and management experience in both private and public companies. Prior to his current position, he was the company’s Chief Financial Officer. Before joining ImpactRx, Mr. Altus served as Chief Operating Officer for Medical Broadcasting Company, a company that was an innovator in the use of online and e-marketing techniques for the pharmaceutical and biotechnology industries.
“I am excited to be at the helm during this important point in the company’s development,” said Mr. Altus. “I appreciate the Board’s support as we continue to build our business and increase the value we provide our customers into 2007 and beyond.”
About ImpactRx
Founded in October 2000, ImpactRx’s physician networks are the source of an unprecedented intelligence capability for tracking the promotional initiatives of the pharmaceutical industry and for measuring their impact on prescribing behavior. Based in Mount Laurel, New Jersey, ImpactRx is a private company with investment financing provided by Mediphase Venture Partners (www.mediphaseventure.com), Oxford Bioscience Partners (www.oxbio.com), Merck Capital Ventures (www.merckcapitalventures.com) and 3i Group (www.3i.com).
CONTACT: Patrick Angelastro Sr. Vice President, Strategic Development ImpactRx, Inc. 856-273-0221, ext. 102 pangelastro@impactrx.com
Source: ImpactRx, Inc.
